Paris, France, December 13th, 2011 – Mauna Kea Technologies (NYSE Euronext: MKEA), the leader in the endomicroscopy market, announced today the publicaton of a new study on colorectal cancer in a leading medical journal, Gastrointestnal Endoscopy (GIE). The study results underline the value of Cellvizio’s probe-based confocal laser endomicroscopy (pCLE) technology in the detecton of residual neoplasia afer colorectal endoscopic mucosal resecton (EMR).
“The study adds to the growing body of clinical evidence demonstratng once again, the value of Cellvizio as an advanced imaging system which facilitates real-tme diagnosis, follow-up and treatment,” said Dr. Emmanuel Coron, Department of Gastroenterology and Hepatology, University Hospital of Nantes, France. “As physicians contnue to advance the use of Cellvizio in the feld of gastroenterology, growing numbers of investgators are using the system to provide enhanced visualizaton of potentally diseased tssue in the digestve and pulmonary systems including lungs, urinary tract and pancreas. Studies of the technology in various applicatons have already been featured in many publicatons of high-profle scientfc journals - including 30 in recent months.”
In comparison to endoscopy alone, fnal study results demonstrate that the combinaton of Cellvizio’s pCLE with virtual chromoendoscopy (VCE) following an EMR in the colon, can help:
• physicians to decide during endoscopy procedures whether a patent requires re-treatment or not;
• reduce the need for repeat follow-up colonoscopies and additonal procedures;
• reduce the need for additonal histologic examinatons (analysis of tssues taken from a biopsy, under a microscope).
The multcenter study was initated by the Mayo Clinic in Jacksonville (FL, USA) and was conducted at three centers, including Nantes University Medical Center (Nantes, France). High-resoluton colonoscopies were performed using pCLE and VCE to detect residual neoplasia in 129 previous EMR scars in 92 patents. The study results have now been published in GIE under the ttle “Diagnostc accuracy of probe-based Confocal Laser Endomicroscopy (pCLE) in detectng residual colorectal neoplasia afer endoscopic mucosal resecton (EMR)”.
Colorectal cancer
Colorectal cancer is a malignant tumor of the colonic or rectal mucosa. The colon and the rectum consttute the last secton of the digestve tract (also referred to as the large intestne). It has been estmated that 60 to 80% of colorectal tumors develop from a benign tumors called polyps or adenomas. Out of 1,000 adenomas, an average of 100 will grow to a size of 1 cm and 25 will become cancerous. The adenoma-cancer transiton takes place over a period of around ten years, on average. Colorectal is ofen initally asymptomatc and is sometmes diagnosed late – requiring the subsequent use of aggressive treatments. According to GLOBCAN, around 60% of cases were diagnosed in the developed world. It is estmated that, in 2008, 1.24 million new cases of colorectal cancer were clinically diagnosed, and that this type of cancer killed 610,000 people.
Cancer is a leading cause of death worldwide and accounted for 7.6 million deaths (around 13% of all deaths) in 20082
The main types of cancer are: lung (1.4 million deaths); stomach (740 000 deaths); liver (700 000 deaths); colorect al (610 000 deaths) and breast (460 000 deaths). About 70% of all cancer deaths occurred in low- and middle-income countries. Deaths from cancer worldwide are projected to contnue to rise to over 11 million in 2030.
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company and a leader in endomicroscopic innovaton. The company designs, develops and markets innovatve tools to visualize and help detect abnormalites in the gastrointestnal and pulmonary tracts. Its fagship product (Cellvizio®, a probe-based confocal laser endomicroscopy (pCLE) system) provides physicians and researchers with high-resoluton cellular views of tssue inside the body. Large, internatonal, multcenter clinical trials have demonstrated Cellvizio®’s ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patent outcomes and reduce hospital costs, Cellvizio can be used with almost any endoscope. Cellvizio® has 510(k) clearance from the U.S. Food and Drug Administraton and the European CE-Mark for use in the gastrointestnal and pulmonary tracts. For more informaton on Mauna Kea Technologies, visit www.maunakeatech.com
Disclaimer
This press release and the informaton contained herein do not consttute an ofer to sell or subscribe to, or a solicitaton of an ofer to buy or subscribe to, shares in Mauna Kea Technologies (“the Company”) in any country. This press release contains forward-looking statements that relate to the Company’s objectves. Such forward-looking statements are based solely on the current expectatons and assumptons of the Company’s management and involve risk and uncertaintes. Potental risks and uncertaintes include, without limitaton, whether the Company will be successful in implementng its strategies, whether there will be contnued growth in the relevant market and demand for the Company’s products, new products or technological developments introduced by compettors, and risks associated with managing growth. Unfavorable developments in connecton with these and other risks and uncertaintes described, in partcular, in the Company’s prospectus prepared in connecton with its IPO and on which the French Autorité des marches fnanciers (“AMF”) granted its visa number 11-236 on June 230, 2011, could cause the Company to fail to achieve the objectves expressed by the forward-looking statements above.
United States
Erich Sandoval
Lazar Partners Ltd.
Tel: +1 917 497 2867
esandoval@lazarpartners.com
France and Europe
ALIZE RP
Caroline Carmagnol
Tel: + 33 1 42 68 86 43 / + 33 6 64 18 99 59
caroline@alizerp.com
Anne–Sophie Cosquéric
Tel: + 33 1 42 68 86 41 / Anne-sophie@alizerp.com
New Cap
Investor Relatons and Financial Communicaton
Pierre Laurent / Florent Alba
Tel: +33 1 44 71 94 94 / maunakea@newcap.fr
Mauna Kea Technologies
Alexander Bryson
Marketng Communicatons and Brand Manager
Tel: +33 (0) 1 70 08 09 92
alexander@maunakeatech.com
